HRP20201467T1 - Nova imunoterapija protiv raznih vrsta karcinoma, uključujući gastrointestinalni karcinom i gastrični karcinom - Google Patents
Nova imunoterapija protiv raznih vrsta karcinoma, uključujući gastrointestinalni karcinom i gastrični karcinom Download PDFInfo
- Publication number
- HRP20201467T1 HRP20201467T1 HRP20201467TT HRP20201467T HRP20201467T1 HR P20201467 T1 HRP20201467 T1 HR P20201467T1 HR P20201467T T HRP20201467T T HR P20201467TT HR P20201467 T HRP20201467 T HR P20201467T HR P20201467 T1 HRP20201467 T1 HR P20201467T1
- Authority
- HR
- Croatia
- Prior art keywords
- peptide
- ctl
- nucleic acid
- host cell
- expression vector
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 3
- 208000005718 Stomach Neoplasms Diseases 0.000 title claims 2
- 206010017758 gastric cancer Diseases 0.000 title claims 2
- 230000002496 gastric effect Effects 0.000 title claims 2
- 201000011549 stomach cancer Diseases 0.000 title claims 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 16
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 239000013604 expression vector Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 2
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 1
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 102000043129 MHC class I family Human genes 0.000 claims 1
- 108091054437 MHC class I family Proteins 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 108010028930 invariant chain Proteins 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
Claims (11)
1. Peptid odabran iz grupe
a) peptid koji se sastoji od slijeda sukladno SEQ ID br. 86,
b) peptid prema a) koji navodi kako peptid uključuje nepeptidne vezove, i
c) peptid prema a), pri čemu je navedeni peptid dio fuzijskog proteina, koji sadrži N-terminalne aminokiseline HLA-DR invarijantnog lanca vezanog za antigene (Ii) za uporabu u medicini.
2. Nukleinska kiselina, koja kodira peptid u skladu s patentnim zahtjevom 1 a) ili c) ili ekspresivni vektor koji može eksprimirati navedenu nukleinsku kiselinu.
3. Stanica domaćin koja sadrži nukleinske kiseline prema zahtjevu 2.
4. Stanica domaćin prema zahtjevu 3, koja stanica predstavlja antigen, kao primjerice dendritične stanice.
5. In vitro metoda za proizvodnju aktiviranih citotoksičnih T-limfocita (CTL), metoda je koja obuhvaća kontaktiranje in vitro CTL-a humanim MHC molekulama klase I s umetnutim antigenima koje se eksprimiraju na površini odgovarajuće stanice koja predstavlja antigen u vremenskom razdoblju dovoljnom da se aktivira navedeni CTL na način svojstven antigenu, pri čemu je navedeni antigen peptid prema zahtjevu 1 a).
6. Aktivirani citotoksični T-limfocit (CTL), proizveden metodom u skladu s patentnim zahtjevom 5, koji selektivno prepoznaje stanicu koja abnormalno eksprimira polipeptid koji sadrži sekvence aminokiselina navedene u patentnom zahtjevu 1 a.
7. Antitijelo koje se posebice veže za MHC/peptidni kompleks, koji sadrži peptid prema zahtjevu 1 a).
8. Peptid prema zahtjevu 1, nukleinska kiselina ili ekspresivni vektor prema zahtjevu 2, stanica domaćin prema zahtjevu 3 ili 4, CTL prema zahtjevu 6, ili antitijelo prema zahtjevu 7, za uporabu kao lijek ili za liječenje karcinoma.
9. Peptid prema zahtjevu 1, nukleinska kiselina ili ekspresivni vektor prema zahtjevu 2, stanica domaćin prema zahtjevu 3 ili 4, CTL prema zahtjevu 6, ili antitijelo prema zahtjevu 7, za uporabu prema zahtjevu 8, u kojem je lijek naveden kao cjepivo.
10. Peptid prema zahtjevu 1, nukleinska kiselina ili ekspresivni vektor prema zahtjevu 2, stanica domaćin prema zahtjevu 3 ili 4, CTL prema zahtjevu 6, ili antitijelo prema zahtjevu 7, za uporabu prema zahtjevu 8 ili 9, u kojem je karcinom gastrični karcinom, gastrointestinalni, karcinom kolona ili rektuma, pankreasa, pluća ili bubrega.
11. In vitro korištenje peptida prema zahtjevu 1 za generiranje ili proizvodnju specifičnih antitijela protiv MHC/peptidnih kompleksa.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31570410P | 2010-03-19 | 2010-03-19 | |
| GBGB1004551.6A GB201004551D0 (en) | 2010-03-19 | 2010-03-19 | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| EP17203096.7A EP3329933B1 (en) | 2010-03-19 | 2011-03-15 | Novel immunotherapy against several tumors including gastrointestinal and gastric cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201467T1 true HRP20201467T1 (hr) | 2020-12-11 |
Family
ID=42227949
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150867TT HRP20150867T1 (hr) | 2010-03-19 | 2015-08-13 | Nova inumoterapija protiv nekoliko tumora ukljuäśujuä†i gastrointestinalni i gastriäśni karcinom |
| HRP20170718TT HRP20170718T1 (hr) | 2010-03-19 | 2017-05-12 | Nova imunoterapija protiv nekoliko tumora uključujući gastrointestinalni i gastrični karcinom |
| HRP20171504TT HRP20171504T1 (hr) | 2010-03-19 | 2017-10-06 | Nova imunoterapija protiv nekoliko tumora uključujući gastrointestinalni i gastrični karcinom |
| HRP20191859TT HRP20191859T1 (hr) | 2010-03-19 | 2019-10-14 | Nova imunoterapija protiv nekoliko tumora uključujući gastrointestinalni i gastrični karcinom |
| HRP20201467TT HRP20201467T1 (hr) | 2010-03-19 | 2020-09-14 | Nova imunoterapija protiv raznih vrsta karcinoma, uključujući gastrointestinalni karcinom i gastrični karcinom |
| HRP20201770TT HRP20201770T1 (hr) | 2010-03-19 | 2020-11-02 | Nova imunoterapija protiv raznih vrsta karcinoma, uključujući gastrointestinalni karcinom i gastrični karcinom |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150867TT HRP20150867T1 (hr) | 2010-03-19 | 2015-08-13 | Nova inumoterapija protiv nekoliko tumora ukljuäśujuä†i gastrointestinalni i gastriäśni karcinom |
| HRP20170718TT HRP20170718T1 (hr) | 2010-03-19 | 2017-05-12 | Nova imunoterapija protiv nekoliko tumora uključujući gastrointestinalni i gastrični karcinom |
| HRP20171504TT HRP20171504T1 (hr) | 2010-03-19 | 2017-10-06 | Nova imunoterapija protiv nekoliko tumora uključujući gastrointestinalni i gastrični karcinom |
| HRP20191859TT HRP20191859T1 (hr) | 2010-03-19 | 2019-10-14 | Nova imunoterapija protiv nekoliko tumora uključujući gastrointestinalni i gastrični karcinom |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201770TT HRP20201770T1 (hr) | 2010-03-19 | 2020-11-02 | Nova imunoterapija protiv raznih vrsta karcinoma, uključujući gastrointestinalni karcinom i gastrični karcinom |
Country Status (30)
| Country | Link |
|---|---|
| US (24) | US10064913B2 (hr) |
| EP (9) | EP3753570B1 (hr) |
| JP (10) | JP5891181B2 (hr) |
| KR (13) | KR101826460B1 (hr) |
| CN (8) | CN112409453A (hr) |
| AU (1) | AU2011229199B2 (hr) |
| BR (1) | BR112012023692B1 (hr) |
| CA (5) | CA3076642C (hr) |
| CY (5) | CY1119366T1 (hr) |
| DK (6) | DK3363456T3 (hr) |
| EA (8) | EA202091242A3 (hr) |
| ES (6) | ES2829375T3 (hr) |
| GB (1) | GB201004551D0 (hr) |
| HK (5) | HK1226297A1 (hr) |
| HR (6) | HRP20150867T1 (hr) |
| HU (6) | HUE033682T2 (hr) |
| LT (5) | LT3363456T (hr) |
| ME (3) | ME02229B (hr) |
| MX (6) | MX2012010813A (hr) |
| MY (2) | MY178651A (hr) |
| NZ (8) | NZ727841A (hr) |
| PH (2) | PH12016500949A1 (hr) |
| PL (6) | PL2923708T3 (hr) |
| PT (6) | PT2547354E (hr) |
| RS (6) | RS54182B1 (hr) |
| SG (4) | SG10201502093QA (hr) |
| SI (6) | SI3329933T1 (hr) |
| TW (9) | TWI659967B (hr) |
| UA (3) | UA126787C2 (hr) |
| WO (1) | WO2011113819A2 (hr) |
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7604662B2 (en) | 2007-07-13 | 2009-10-20 | Boston Scientific Scimed, Inc. | Endoprostheses containing boride intermetallic phases |
| ES2536465T3 (es) | 2008-10-01 | 2015-05-25 | Immatics Biotechnologies Gmbh | Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres |
| GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201004575D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
| EP2400035A1 (en) * | 2010-06-28 | 2011-12-28 | Technische Universität München | Methods and compositions for diagnosing gastrointestinal stromal tumors |
| US9040046B2 (en) | 2011-01-31 | 2015-05-26 | Kai Xu | Sodium pump antibody agonists and methods of treating heart disease using the same |
| ES2665576T3 (es) * | 2011-10-28 | 2018-04-26 | Oncotherapy Science, Inc. | Péptidos TOPK y vacunas que los incluyen |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| CA2902415C (en) * | 2012-03-19 | 2024-02-06 | Stemline Therapeutics, Inc. | Methods for treating and monitoring the status of cancer |
| WO2013173411A1 (en) | 2012-05-16 | 2013-11-21 | Stemline Therapeutics, Inc | Cancer stem cell targeted cancer vaccines |
| JP6255593B2 (ja) * | 2012-07-10 | 2018-01-10 | オンコセラピー・サイエンス株式会社 | Ｔｈ１細胞のＣＤＣＡ１エピトープペプチドおよびこれを含有するワクチン |
| WO2014014518A1 (en) * | 2012-07-18 | 2014-01-23 | Dana-Farber Cancer Institute, Inc. | Methods for treating, preventing and predicting risk of developing breast cancer |
| JP6212249B2 (ja) * | 2012-08-08 | 2017-10-11 | 学校法人 京都産業大学 | カルシウムポンプ制御物質のスクリーニング方法、並びに、メラニン色素合成阻害物質のスクリーニング方法 |
| GB2521562B (en) | 2012-08-30 | 2020-07-08 | Univ Leland Stanford Junior | Anti-tumor T cell immunity induced by high dose radiation |
| TWI775117B (zh) * | 2013-08-05 | 2022-08-21 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（二） |
| ES2900004T3 (es) | 2013-08-05 | 2022-03-15 | Immatics Biotechnologies Gmbh | Nueva inmunoterapia contra diversos tumores como el cáncer de pulmón, incluido el carcinoma de pulmón amicrocítico (NSCLC) |
| EP2876442A1 (en) * | 2013-11-22 | 2015-05-27 | Institut de Cancérologie de l'Ouest | Olfactomedin-4, neudesin and desmoplakin as biomarkers of breast cancer |
| CA2935960C (en) | 2014-01-08 | 2023-01-10 | Bart Lipkens | Acoustophoresis device with dual acoustophoretic chamber |
| US10532088B2 (en) | 2014-02-27 | 2020-01-14 | Lycera Corporation | Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods |
| EP3134114A4 (en) * | 2014-04-24 | 2018-03-14 | Rhode Island Hospital | Aspartate-beta -hydroxylase induces epitope-specific t cell responses in tumors |
| US9896441B2 (en) | 2014-05-05 | 2018-02-20 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
| US10189777B2 (en) | 2014-05-05 | 2019-01-29 | Lycera Corporation | Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease |
| GB201408255D0 (en) * | 2014-05-09 | 2014-06-25 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML) |
| KR101644599B1 (ko) | 2014-10-14 | 2016-08-16 | 연세대학교 산학협력단 | 미토콘드리아 단백질 uqcrb 관련 질환 유전자발현 세포 구축 및 이를 활용한 uqcrb 기능조절 활성평가계 구축 |
| MA40737A (fr) * | 2014-11-21 | 2017-07-04 | Memorial Sloan Kettering Cancer Center | Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1 |
| GB201423361D0 (en) * | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| IL284985B2 (en) | 2015-02-18 | 2023-03-01 | Enlivex Therapeutics R& D Ltd | Combined immunotherapy and cytokine control therapy for cancer treatment |
| GB201504502D0 (en) * | 2015-03-17 | 2015-04-29 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers |
| CR20210232A (es) | 2015-03-17 | 2022-06-24 | Immatics Biotechnologies Gmbh | NUEVOS PÉPTIDOS Y NUEVA COMBINACIÓN DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CÁNCER DE PÁNCREAS Y OTROS TIPOS DE CÁNCER (Divisional 2017-0419) |
| EP4140492A1 (en) | 2015-04-21 | 2023-03-01 | Enlivex Therapeutics Rdo Ltd | Therapeutic pooled blood apoptotic cell preparations and uses thereof |
| GB201507030D0 (en) | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US10421751B2 (en) | 2015-05-05 | 2019-09-24 | Lycera Corporation | Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| WO2016201225A1 (en) | 2015-06-11 | 2016-12-15 | Lycera Corporation | Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of rory and the treatment of disease |
| CN107864654B (zh) * | 2015-06-19 | 2022-03-15 | 伊玛提克斯生物技术有限公司 | 用于免疫治疗的新型肽和肽组合物以及用于胰腺癌和其他癌症的支架产生方法 |
| GB201510771D0 (en) | 2015-06-19 | 2015-08-05 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| EP3919507A3 (en) | 2015-07-01 | 2022-01-12 | Immatics Biotechnologies GmbH | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| GB201512369D0 (en) * | 2015-07-15 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
| US10159726B2 (en) * | 2015-08-28 | 2018-12-25 | Immatics Biotechnologies Gmbh | Peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| GB201515321D0 (en) | 2015-08-28 | 2015-10-14 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| TWI796642B (zh) | 2015-08-28 | 2023-03-21 | 德商英麥提克生物技術股份有限公司 | 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架 |
| KR102601499B1 (ko) * | 2015-11-06 | 2023-11-13 | 연세대학교 산학협력단 | miRNA 발현 수준으로부터 UQCRB 관련 질병을 진단하는 방법 |
| GB201521746D0 (en) * | 2015-12-10 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers |
| MX2018007204A (es) | 2015-12-16 | 2018-12-11 | Gritstone Oncology Inc | Identificacion, fabricacion y uso de neoantigeno. |
| KR20180110141A (ko) | 2016-02-18 | 2018-10-08 | 엔리벡스 테라퓨틱스 리미티드 | 암을 치료하기 위한 면역요법과 사이토카인 조절 요법의 조합 |
| GB201603568D0 (en) * | 2016-03-01 | 2016-04-13 | Immatics Biotechnologies Gmbh | Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer |
| IL302705A (en) | 2016-03-01 | 2023-07-01 | Immatics Biotechnologies Gmbh | Peptides, combinations of peptides, cell-based drugs for use in immunotherapy against bladder cancer and other types of cancer |
| GB201603987D0 (en) * | 2016-03-08 | 2016-04-20 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| GB201604490D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides combination of peptides for use in immunotherapy against cancers |
| GB201604458D0 (en) * | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| PE20181897A1 (es) | 2016-04-21 | 2018-12-11 | Immatics Biotechnologies Gmbh | Inmunoterapia contra el melanoma y otros tipos de cancer |
| CR20200607A (es) | 2016-04-21 | 2021-01-20 | Immatics Biotechnologies Gmbh | INMUNOTERAPIA CONTRA EL MELANOMA Y OTROS TIPOS DE CÁNCER (Divisional 2018-551) |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| DE102016115246C5 (de) | 2016-08-17 | 2018-12-20 | Immatics Biotechnologies Gmbh | Neue t-zellrezeptoren und deren verwendung in immuntherapie |
| HRP20211677T1 (hr) * | 2016-08-17 | 2022-02-18 | Immatics Biotechnologies Gmbh | T-stanični receptori i imunološka terapija koja koristi iste |
| ZA201900664B (en) | 2016-08-17 | 2021-09-29 | Paul Ehrlich Strasse 15 Tuebingen 72076 Germany | T cell receptors and immune therapy using the same |
| CN109923121B (zh) | 2016-11-22 | 2022-12-23 | 武汉华大吉诺因生物科技有限公司 | 多肽及其应用 |
| WO2018098715A1 (zh) * | 2016-11-30 | 2018-06-07 | 深圳华大基因研究院 | 多肽及其应用 |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| NZ754222A (en) | 2016-12-08 | 2022-02-25 | Immatics Biotechnologies Gmbh | T cell receptors with improved pairing |
| CN111533798A (zh) * | 2017-04-10 | 2020-08-14 | 伊玛提克斯生物技术有限公司 | 用于癌症免疫治疗的肽及其肽组合物 |
| TW201841934A (zh) | 2017-04-10 | 2018-12-01 | 德商英麥提克生物技術股份有限公司 | 用於治療癌症免疫治療的新穎肽及其肽組合物 |
| SG11202000025SA (en) | 2017-07-14 | 2020-02-27 | Immatics Biotechnologies Gmbh | Improved dual specificity polypeptide molecule |
| DE102017115966A1 (de) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Polypeptidmolekül mit verbesserter zweifacher Spezifität |
| CA3078744A1 (en) | 2017-10-10 | 2019-04-18 | Gritstone Oncology, Inc. | Neoantigen identification using hotspots |
| ES2941965T3 (es) * | 2017-11-06 | 2023-05-29 | Immatics Biotechnologies Gmbh | Nuevos receptores de linfocito T genomanipulados e inmunoterapias basadas en el uso de los mismos |
| DE102017125888A1 (de) * | 2017-11-06 | 2019-05-23 | Immatics Biotechnologies Gmbh | Neue konstruierte T-Zell-Rezeptoren und deren Verwendung in Immuntherapie |
| CA3083097A1 (en) | 2017-11-22 | 2019-05-31 | Gritstone Oncology, Inc. | Reducing junction epitope presentation for neoantigens |
| SG11202003907WA (en) | 2017-12-14 | 2020-05-28 | Flodesign Sonics Inc | Acoustic transducer drive and controller |
| WO2020081537A1 (en) * | 2018-10-16 | 2020-04-23 | Texas Tech University System | Method to express, purify, and biotinylate eukaryotic cell-derived major histocompatibility complexes |
| AU2020283500A1 (en) | 2019-05-27 | 2022-01-27 | Immatics US, Inc. | Viral vectors and their use in adoptive cellular therapy |
| DE102019114735A1 (de) * | 2019-06-02 | 2020-12-03 | PMCR GmbH | HLA-Tumorantigenpeptiden der Klasse I und II zur Behandlung von Mamma-/Brustkarzinomen |
| MX2021015033A (es) | 2019-06-06 | 2022-01-18 | Immatics Biotechnologies Gmbh | Clasificacion con contraseleccion utilizando peptidos de secuencias similares. |
| KR102397922B1 (ko) * | 2020-02-19 | 2022-05-13 | 서울대학교 산학협력단 | 신규한 종양-관련 항원 단백질 olfm4 및 이의 용도 |
| WO2022045768A1 (ko) | 2020-08-28 | 2022-03-03 | 계명대학교 산학협력단 | 당뇨병 치료제에 대한 약물반응성 예측용 마이크로 rna 바이오마커 및 이의 용도 |
| EP4247402A1 (en) * | 2020-11-19 | 2023-09-27 | Board of Regents, The University of Texas System | Methods and compositions comprising mhc class i peptides |
| DE102021100038A1 (de) | 2020-12-31 | 2022-06-30 | Immatics US, Inc. | Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung |
| JP2024502034A (ja) | 2020-12-31 | 2024-01-17 | イマティクス ユーエス，アイエヌシー． | Ｃｄ８ポリペプチド、組成物、及びそれらの使用方法 |
| BR112023022975A2 (pt) | 2021-05-05 | 2024-01-23 | Immatics Biotechnologies Gmbh | Polipeptídeos de ligação ao antígeno bma031 melhorados |
| CN114732898B (zh) * | 2022-04-01 | 2023-05-09 | 中国人民解放军军事科学院军事医学研究院 | 一种CpG佐剂与抗原定点共价结合方法 |
| US20240066127A1 (en) | 2022-04-28 | 2024-02-29 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| WO2023212691A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF |
| US20230348548A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| US20230355678A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
| WO2024072954A1 (en) * | 2022-09-29 | 2024-04-04 | Jerome Canady Research Institute for Advanced Biological and Technological Sciences | Cold atmopsheric plasma treated pan-cancer epitope peptide within the collagen type vi a-3 (col6a3) protein as cancer vaccine |
| WO2024077071A2 (en) * | 2022-10-05 | 2024-04-11 | The Johns Hopkins University | Nanoparticles for delivery of immunoregulatory materials to t cells |
| WO2024168055A1 (en) * | 2023-02-08 | 2024-08-15 | Navigen, Inc. | Tnf-alpha binding agents and methods of using the same |
| CN116102468B (zh) * | 2023-02-22 | 2024-07-09 | 中国科学技术大学 | 靶向人脂质运载蛋白2的先导化合物或其药学上可接受的盐及其制备方法与应用 |
| WO2024225764A1 (ko) * | 2023-04-26 | 2024-10-31 | 한국과학기술원 | 섬유아세포 활성화 단백질의 면역우세 에피토프 펩타이드 및 이의 용도 |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| NO794196L (no) | 1978-12-22 | 1980-06-24 | Biogen Nv | Fremgangsmaate ved fremstilling av et rekombinert dna molekyl |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
| ES2108460T3 (es) | 1993-06-03 | 1997-12-16 | Therapeutic Antibodies Inc | Fragmentos de anticuerpos en terapeutica. |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| ATE244300T1 (de) | 1996-01-17 | 2003-07-15 | Imp College Innovations Ltd | Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl) |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US8299321B2 (en) | 1998-06-16 | 2012-10-30 | Monsanto Technology Llc | Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
| CA2343934A1 (en) * | 1998-09-25 | 2000-04-06 | The Children's Medical Center Corporation | Short peptides which selectively modulate the activity of protein kinases |
| AU3395900A (en) * | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
| WO2001041787A1 (en) * | 1999-12-10 | 2001-06-14 | Epimmune Inc. | INDUCING CELLULAR IMMUNE RESPONSES TO HER2/neu USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS |
| JP4310104B2 (ja) | 2002-09-28 | 2009-08-05 | 英俊 猪子 | マイクロサテライト遺伝多型マーカを用いる遺伝子のマッピング方法 |
| US20110131679A2 (en) | 2000-04-19 | 2011-06-02 | Thomas La Rosa | Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement |
| US20070067865A1 (en) | 2000-09-05 | 2007-03-22 | Kovalic David K | Annotated plant genes |
| EP1317275A1 (de) * | 2000-09-06 | 2003-06-11 | Müller, Friederike | Arzneimittel mit einer für das rna-bindende koc-protein kodierenden dna-sequenz, einem koc-protein oder einer dna-sequenz des koc-promotors |
| JP2004528810A (ja) | 2000-10-02 | 2004-09-24 | バイエル コーポレーション | 癌組織でディファレンシャルに発現される核酸配列 |
| US6673549B1 (en) * | 2000-10-12 | 2004-01-06 | Incyte Corporation | Genes expressed in C3A liver cell cultures treated with steroids |
| USH2191H1 (en) | 2000-10-24 | 2007-06-05 | Snp Consortium | Identification and mapping of single nucleotide polymorphisms in the human genome |
| EP1538163A3 (en) * | 2000-11-01 | 2005-06-15 | Insight Biotechnology Limited | Phosphorylated Amyloid-Beta 1-43 Protein and its use in the treatment of Alzheimer's disease |
| US7919467B2 (en) * | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| AU2002311787A1 (en) * | 2001-03-28 | 2002-10-15 | Zycos Inc. | Translational profiling |
| AU2002303219A1 (en) * | 2001-03-30 | 2002-10-15 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of cancer |
| US20040025202A1 (en) | 2002-03-15 | 2004-02-05 | Laurie Cathy C. | Nucleic acid molecules associated with oil in plants |
| DE10225139A1 (de) * | 2002-05-29 | 2004-02-26 | Immatics Biotechnologies Gmbh | Verfahren zur Identifizierung von immunreaktiven Peptiden |
| US20050221350A1 (en) * | 2002-05-29 | 2005-10-06 | Toni Weinschenk | Method for identifying immunoreactive peptides |
| WO2004014867A2 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Matrix metalloproteinase inhibitors and methods for identification of lead compounds |
| US20060188889A1 (en) * | 2003-11-04 | 2006-08-24 | Christopher Burgess | Use of differentially expressed nucleic acid sequences as biomarkers for cancer |
| WO2005049806A2 (en) * | 2003-03-14 | 2005-06-02 | Nuvelo, Inc. | Novel nucleic acids and polypeptides |
| US20070037204A1 (en) * | 2003-08-08 | 2007-02-15 | Hiroyuki ABURANTAI | Gene overexpressed in cancer |
| WO2005019258A2 (en) * | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US20070054278A1 (en) | 2003-11-18 | 2007-03-08 | Applera Corporation | Polymorphisms in nucleic acid molecules encoding human enzyme proteins, methods of detection and uses thereof |
| CA2554440A1 (en) * | 2004-01-27 | 2005-08-11 | Compugen Usa, Inc. | Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of breast cancer |
| EP1568383A3 (en) | 2004-02-27 | 2005-11-16 | Antisense Pharma GmbH | Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment |
| US20070039069A1 (en) | 2004-03-22 | 2007-02-15 | Rogers James A | Nucleic acid molecules associated with oil in plants |
| DE602005025998D1 (de) | 2004-03-23 | 2011-03-03 | Oncotherapy Science Inc | Verfahren zur diagnose von nicht-kleinzelligem lungenkrebs |
| AT501014A1 (de) * | 2004-08-19 | 2006-05-15 | Kury & Zeillinger Oeg | Verfahren und kit zur diagnose einer krebserkrankung, verfahren zum feststellen des ansprechens eines patienten auf die behandlung einer krebserkrankung, therapeutikum zur prophylaxe oder behandlung einer krebserkrankung |
| WO2006023598A2 (en) * | 2004-08-19 | 2006-03-02 | University Of Maryland, Baltimore | Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer |
| WO2007005635A2 (en) * | 2005-07-01 | 2007-01-11 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mitotic spindle protein aspm as a diagnostic marker for neoplasia and uses therefor |
| EP1760089B1 (en) * | 2005-09-05 | 2009-08-19 | Immatics Biotechnologies GmbH | Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine |
| PT1806359E (pt) * | 2005-09-05 | 2010-05-25 | Immatics Biotechnologies Gmbh | Peptídeos associados a tumor ligando promiscuamente às moléculas do antigénio de leucócitos humanos (hla) da classe ii |
| GB0521958D0 (en) | 2005-10-27 | 2005-12-07 | Ares Trading Sa | vWFA, collagen and kunitz domain containing protein |
| DE102005052384B4 (de) * | 2005-10-31 | 2009-09-24 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Verfahren zur Erkennung, Markierung und Behandlung von epithelialen Lungentumorzellen sowie Mittel zur Durchführung des Verfahrens |
| US20090004213A1 (en) * | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
| AU2008281014B2 (en) * | 2007-07-27 | 2012-06-28 | Immatics Biotechnologies Gmbh | Novel immunogenic epitopes for immunotherapy |
| LT2567707T (lt) | 2007-07-27 | 2017-01-10 | Immatics Biotechnologies Gmbh | Su naviku susijusių peptidų kompozicija ir susijusi priešvėžinė vakcina |
| US7892770B2 (en) * | 2007-08-24 | 2011-02-22 | Van Andel Research Institute | Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods |
| NZ562237A (en) * | 2007-10-05 | 2011-02-25 | Pacific Edge Biotechnology Ltd | Proliferation signature and prognosis for gastrointestinal cancer |
| WO2009075883A2 (en) * | 2007-12-12 | 2009-06-18 | University Of Georgia Research Foundation, Inc. | Glycoprotein cancer biomarker |
| KR101184869B1 (ko) * | 2008-04-24 | 2012-09-20 | 이매틱스 바이오테크놀로지스 게엠베하 | 백신을 위한 인간 조직 적합성 항원(ｈｌａ) 종류 ｉ 또는 ｉｉ 분자에 결합하는 종양 관련 펩티드의 신규한 제형 |
| ES2342506T3 (es) | 2008-04-30 | 2010-07-07 | Immatics Biotechnologies Gmbh | Novedosas formulaciones para vacunas de peptidos asociados a tumores, unidos a moleculas del antigeno de leucocito humano (hla) de clase i o ii. |
| US8133686B2 (en) * | 2008-05-15 | 2012-03-13 | Van Andel Research Institute | IL-8 as a biomarker for sunitinib resistance |
| TWI526219B (zh) * | 2008-06-19 | 2016-03-21 | 腫瘤療法 科學股份有限公司 | Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗 |
| WO2010037395A2 (en) * | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| ES2536465T3 (es) * | 2008-10-01 | 2015-05-25 | Immatics Biotechnologies Gmbh | Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres |
| GB201019331D0 (en) * | 2010-03-19 | 2010-12-29 | Immatics Biotechnologies Gmbh | Methods for the diagnosis and treatment of cancer based on AVL9 |
| GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201004575D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
| GB201006360D0 (en) * | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| GB201015765D0 (en) * | 2010-09-21 | 2010-10-27 | Immatics Biotechnologies Gmbh | Use of myeloid cell biomarkers for the diagnosis of cancer |
| GB201021289D0 (en) * | 2010-12-15 | 2011-01-26 | Immatics Biotechnologies Gmbh | Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer |
-
2010
- 2010-03-19 GB GBGB1004551.6A patent/GB201004551D0/en not_active Ceased
-
2011
- 2011-03-15 CA CA3076642A patent/CA3076642C/en active Active
- 2011-03-15 PL PL15154344T patent/PL2923708T3/pl unknown
- 2011-03-15 EA EA202091242A patent/EA202091242A3/ru unknown
- 2011-03-15 PT PT117112920T patent/PT2547354E/pt unknown
- 2011-03-15 RS RS20150530A patent/RS54182B1/en unknown
- 2011-03-15 LT LTEP18156634.0T patent/LT3363456T/lt unknown
- 2011-03-15 KR KR1020167023720A patent/KR101826460B1/ko active IP Right Grant
- 2011-03-15 SI SI201131913T patent/SI3329933T1/sl unknown
- 2011-03-15 RS RS20201054A patent/RS60765B1/sr unknown
- 2011-03-15 LT LTEP14184348.2T patent/LT2845604T/lt unknown
- 2011-03-15 CN CN202011080378.9A patent/CN112409453A/zh active Pending
- 2011-03-15 JP JP2012557522A patent/JP5891181B2/ja active Active
- 2011-03-15 DK DK18156634.0T patent/DK3363456T3/da active
- 2011-03-15 PL PL18156634T patent/PL3363456T3/pl unknown
- 2011-03-15 NZ NZ72784111A patent/NZ727841A/en not_active IP Right Cessation
- 2011-03-15 UA UAA201801266A patent/UA126787C2/uk unknown
- 2011-03-15 PL PL17203096T patent/PL3329933T3/pl unknown
- 2011-03-15 CA CA2936642A patent/CA2936642C/en active Active
- 2011-03-15 DK DK15154344.4T patent/DK2923708T3/en active
- 2011-03-15 KR KR1020127027196A patent/KR101656913B1/ko active IP Right Grant
- 2011-03-15 EA EA201690511A patent/EA039357B1/ru unknown
- 2011-03-15 ES ES18156634T patent/ES2829375T3/es active Active
- 2011-03-15 HU HUE15154344A patent/HUE033682T2/en unknown
- 2011-03-15 NZ NZ601438A patent/NZ601438A/en not_active IP Right Cessation
- 2011-03-15 ES ES14184348.2T patent/ES2626798T3/es active Active
- 2011-03-15 RS RS20201304A patent/RS60993B1/sr unknown
- 2011-03-15 HU HUE14184348A patent/HUE032402T2/en unknown
- 2011-03-15 KR KR1020197005246A patent/KR20190033577A/ko not_active Application Discontinuation
- 2011-03-15 ME MEP-2015-122A patent/ME02229B/me unknown
- 2011-03-15 KR KR1020207026524A patent/KR102388577B1/ko active IP Right Grant
- 2011-03-15 ES ES17157398T patent/ES2753206T3/es active Active
- 2011-03-15 EP EP20179380.9A patent/EP3753570B1/en active Active
- 2011-03-15 PL PL14184348T patent/PL2845604T3/pl unknown
- 2011-03-15 SI SI201131182A patent/SI2845604T1/sl unknown
- 2011-03-15 EP EP16156192.3A patent/EP3058947A3/en not_active Withdrawn
- 2011-03-15 EP EP17157398.3A patent/EP3195873B1/en active Active
- 2011-03-15 LT LTEP15154344.4T patent/LT2923708T/lt unknown
- 2011-03-15 UA UAA201512437A patent/UA122047C2/uk unknown
- 2011-03-15 PT PT171573983T patent/PT3195873T/pt unknown
- 2011-03-15 PT PT151543444T patent/PT2923708T/pt unknown
- 2011-03-15 EP EP17203096.7A patent/EP3329933B1/en active Active
- 2011-03-15 KR KR1020227004088A patent/KR20220025133A/ko not_active Application Discontinuation
- 2011-03-15 KR KR1020217004318A patent/KR102329791B1/ko active IP Right Grant
- 2011-03-15 SI SI201130546T patent/SI2547354T1/sl unknown
- 2011-03-15 DK DK11711292.0T patent/DK2547354T3/da active
- 2011-03-15 CN CN201510354965.5A patent/CN105001339B/zh active Active
- 2011-03-15 NZ NZ708205A patent/NZ708205A/en not_active IP Right Cessation
- 2011-03-15 EP EP18156634.0A patent/EP3363456B1/en active Active
- 2011-03-15 ES ES15154344.4T patent/ES2642562T3/es active Active
- 2011-03-15 NZ NZ769427A patent/NZ769427A/en not_active IP Right Cessation
- 2011-03-15 RS RS20191340A patent/RS59554B1/sr unknown
- 2011-03-15 CN CN201180014644.0A patent/CN102905721B/zh active Active
- 2011-03-15 CN CN202011079527.XA patent/CN112457390A/zh active Pending
- 2011-03-15 UA UAA201209114A patent/UA111711C2/uk unknown
- 2011-03-15 ME MEP-2017-87A patent/ME02692B/me unknown
- 2011-03-15 CN CN202011079539.2A patent/CN112409451B/zh active Active
- 2011-03-15 LT LTEP17203096.7T patent/LT3329933T/lt unknown
- 2011-03-15 HU HUE17157398A patent/HUE045757T2/hu unknown
- 2011-03-15 PL PL11711292T patent/PL2547354T3/pl unknown
- 2011-03-15 KR KR1020207026525A patent/KR102324498B1/ko active IP Right Grant
- 2011-03-15 EA EA202091251A patent/EA202091251A3/ru unknown
- 2011-03-15 ES ES11711292.0T patent/ES2544529T3/es active Active
- 2011-03-15 US US13/635,896 patent/US10064913B2/en active Active
- 2011-03-15 NZ NZ711296A patent/NZ711296A/en unknown
- 2011-03-15 CA CA3206214A patent/CA3206214A1/en active Pending
- 2011-03-15 SG SG10201502093QA patent/SG10201502093QA/en unknown
- 2011-03-15 EP EP20179386.6A patent/EP3738606B1/en active Active
- 2011-03-15 NZ NZ627877A patent/NZ627877A/en not_active IP Right Cessation
- 2011-03-15 LT LT17157398T patent/LT3195873T/lt unknown
- 2011-03-15 NZ NZ795528A patent/NZ795528A/en unknown
- 2011-03-15 MX MX2012010813A patent/MX2012010813A/es active IP Right Grant
- 2011-03-15 EA EA202091241A patent/EA202091241A3/ru unknown
- 2011-03-15 HU HUE11711292A patent/HUE027036T2/en unknown
- 2011-03-15 EP EP14184348.2A patent/EP2845604B1/en active Active
- 2011-03-15 HU HUE18156634A patent/HUE051478T2/hu unknown
- 2011-03-15 SI SI201131927T patent/SI3363456T1/sl unknown
- 2011-03-15 EP EP11711292.0A patent/EP2547354B1/en active Active
- 2011-03-15 KR KR1020217004319A patent/KR102361467B1/ko active IP Right Grant
- 2011-03-15 NZ NZ769435A patent/NZ769435A/en unknown
- 2011-03-15 SG SG10201606771SA patent/SG10201606771SA/en unknown
- 2011-03-15 DK DK17157398.3T patent/DK3195873T3/da active
- 2011-03-15 PL PL17157398T patent/PL3195873T3/pl unknown
- 2011-03-15 KR KR1020237031847A patent/KR20230141886A/ko active Search and Examination
- 2011-03-15 SG SG2012065173A patent/SG183880A1/en unknown
- 2011-03-15 DK DK17203096.7T patent/DK3329933T3/da active
- 2011-03-15 HU HUE17203096A patent/HUE050376T2/hu unknown
- 2011-03-15 DK DK14184348.2T patent/DK2845604T3/da active
- 2011-03-15 RS RS20170553A patent/RS56070B1/sr unknown
- 2011-03-15 PT PT141843482T patent/PT2845604T/pt unknown
- 2011-03-15 PT PT181566340T patent/PT3363456T/pt unknown
- 2011-03-15 RS RS20170980A patent/RS56612B1/sr unknown
- 2011-03-15 EA EA201792409A patent/EA037019B1/ru unknown
- 2011-03-15 ES ES17203096T patent/ES2819861T3/es active Active
- 2011-03-15 KR KR1020187002782A patent/KR20180014848A/ko not_active Application Discontinuation
- 2011-03-15 CN CN202011079575.9A patent/CN112409452A/zh active Pending
- 2011-03-15 AU AU2011229199A patent/AU2011229199B2/en not_active Ceased
- 2011-03-15 KR KR1020207026527A patent/KR102388761B1/ko active IP Right Grant
- 2011-03-15 EA EA202091250A patent/EA202091250A3/ru unknown
- 2011-03-15 CN CN201810105798.4A patent/CN108456242A/zh active Pending
- 2011-03-15 MY MYPI2012700609A patent/MY178651A/en unknown
- 2011-03-15 EA EA201201306A patent/EA024497B1/ru unknown
- 2011-03-15 SG SG10201710446PA patent/SG10201710446PA/en unknown
- 2011-03-15 CN CN202011080388.2A patent/CN112430255A/zh active Pending
- 2011-03-15 PT PT172030967T patent/PT3329933T/pt unknown
- 2011-03-15 SI SI201131293T patent/SI2923708T1/sl unknown
- 2011-03-15 EP EP15154344.4A patent/EP2923708B1/en active Active
- 2011-03-15 KR KR1020207026532A patent/KR102324499B1/ko active IP Right Grant
- 2011-03-15 BR BR112012023692A patent/BR112012023692B1/pt active IP Right Grant
- 2011-03-15 WO PCT/EP2011/053863 patent/WO2011113819A2/en active Application Filing
- 2011-03-15 ME MEP-2019-287A patent/ME03569B/me unknown
- 2011-03-15 EA EA202091233A patent/EA202091233A3/ru unknown
- 2011-03-15 KR KR1020207026530A patent/KR102324500B1/ko active IP Right Grant
- 2011-03-15 SI SI201131804T patent/SI3195873T1/sl unknown
- 2011-03-15 CA CA2789857A patent/CA2789857C/en active Active
- 2011-03-15 CA CA2986969A patent/CA2986969C/en active Active
- 2011-03-18 TW TW106141450A patent/TWI659967B/zh active
- 2011-03-18 TW TW108144354A patent/TWI715332B/zh not_active IP Right Cessation
- 2011-03-18 TW TW111118219A patent/TW202300509A/zh unknown
- 2011-03-18 TW TW100109429A patent/TWI486445B/zh active
- 2011-03-18 TW TW109130851A patent/TWI766361B/zh active
- 2011-03-18 TW TW109130850A patent/TWI768461B/zh not_active IP Right Cessation
- 2011-03-18 TW TW109130852A patent/TWI766362B/zh active
- 2011-03-18 TW TW104113109A patent/TWI621709B/zh active
- 2011-03-18 US US13/051,665 patent/US9101585B2/en active Active
- 2011-03-18 TW TW107110964A patent/TWI681967B/zh not_active IP Right Cessation
-
2012
- 2012-09-06 MY MYPI2016002170A patent/MY197710A/en unknown
- 2012-09-19 MX MX2020011673A patent/MX2020011673A/es unknown
- 2012-09-19 MX MX2020011675A patent/MX2020011675A/es unknown
- 2012-09-19 MX MX2020011672A patent/MX2020011672A/es unknown
- 2012-09-19 MX MX2020011674A patent/MX2020011674A/es unknown
- 2012-09-19 MX MX2015001606A patent/MX355074B/es unknown
-
2013
- 2013-07-10 HK HK16114573A patent/HK1226297A1/zh unknown
- 2013-07-10 HK HK13108075.6A patent/HK1180610A1/xx not_active IP Right Cessation
- 2013-07-10 HK HK15108854.1A patent/HK1208174A1/xx not_active IP Right Cessation
- 2013-07-10 HK HK18114534.4A patent/HK1255544A1/zh not_active IP Right Cessation
-
2015
- 2015-02-06 US US14/615,539 patent/US9717774B2/en active Active
- 2015-08-13 HR HRP20150867TT patent/HRP20150867T1/hr unknown
- 2015-08-25 JP JP2015165375A patent/JP6103608B2/ja not_active Expired - Fee Related
- 2015-10-20 HK HK15110276.7A patent/HK1210586A1/xx unknown
-
2016
- 2016-05-23 PH PH12016500949A patent/PH12016500949A1/en unknown
- 2016-08-05 JP JP2016154278A patent/JP6238258B2/ja not_active Expired - Fee Related
-
2017
- 2017-02-22 JP JP2017030876A patent/JP6535040B2/ja active Active
- 2017-05-04 CY CY20171100486T patent/CY1119366T1/el unknown
- 2017-05-12 HR HRP20170718TT patent/HRP20170718T1/hr unknown
- 2017-06-28 US US15/636,486 patent/US20170304399A1/en not_active Abandoned
- 2017-06-29 US US15/636,958 patent/US9895415B2/en active Active
- 2017-06-30 US US15/639,506 patent/US10357540B2/en active Active
- 2017-06-30 US US15/639,310 patent/US9993523B2/en active Active
- 2017-10-06 HR HRP20171504TT patent/HRP20171504T1/hr unknown
- 2017-10-10 CY CY20171101050T patent/CY1119739T1/el unknown
- 2017-11-22 JP JP2017224260A patent/JP6722644B2/ja active Active
-
2019
- 2019-05-22 US US16/419,818 patent/US10420816B1/en active Active
- 2019-07-03 US US16/502,268 patent/US10478471B2/en active Active
- 2019-09-24 PH PH12019502194A patent/PH12019502194A1/en unknown
- 2019-10-14 HR HRP20191859TT patent/HRP20191859T1/hr unknown
- 2019-10-18 CY CY20191101092T patent/CY1122235T1/el unknown
- 2019-12-13 US US16/714,098 patent/US10905741B2/en active Active
-
2020
- 2020-06-05 US US16/894,212 patent/US10933118B2/en active Active
- 2020-06-05 US US16/894,186 patent/US10898546B2/en active Active
- 2020-06-19 JP JP2020106500A patent/JP7034505B2/ja active Active
- 2020-06-19 JP JP2020106497A patent/JP7107586B2/ja active Active
- 2020-09-14 HR HRP20201467TT patent/HRP20201467T1/hr unknown
- 2020-09-22 CY CY20201100894T patent/CY1123447T1/el unknown
- 2020-11-02 HR HRP20201770TT patent/HRP20201770T1/hr unknown
- 2020-11-04 CY CY20201101040T patent/CY1123762T1/el unknown
-
2021
- 2021-01-28 US US17/161,253 patent/US11077171B2/en active Active
- 2021-02-05 JP JP2021017733A patent/JP7007504B2/ja active Active
- 2021-04-23 US US17/238,943 patent/US11850274B2/en active Active
- 2021-05-14 US US17/320,782 patent/US11883462B2/en active Active
- 2021-05-21 US US17/327,116 patent/US11839643B2/en active Active
- 2021-06-25 US US17/358,676 patent/US11969455B2/en active Active
- 2021-07-23 US US17/383,855 patent/US11957730B2/en active Active
- 2021-07-23 US US17/383,892 patent/US11975042B2/en active Active
- 2021-09-24 US US17/484,703 patent/US11273200B2/en active Active
- 2021-09-24 US US17/484,568 patent/US20220008506A1/en active Pending
- 2021-10-01 US US17/492,219 patent/US11298404B2/en active Active
- 2021-10-01 US US17/491,742 patent/US12064465B2/en active Active
-
2022
- 2022-04-29 US US17/733,260 patent/US11648292B2/en active Active
- 2022-07-06 JP JP2022108874A patent/JP2022141743A/ja active Pending
-
2024
- 2024-06-12 JP JP2024095464A patent/JP2024116331A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201467T1 (hr) | Nova imunoterapija protiv raznih vrsta karcinoma, uključujući gastrointestinalni karcinom i gastrični karcinom | |
| HRP20201228T1 (hr) | Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga | |
| HRP20201281T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv epitelnog karcinoma jajnika i drugih karcinoma | |
| HRP20210709T1 (hr) | Peptidi i kombinacija peptida za imunoterapiju protiv karcinoma prostate i druge vrste karcinoma | |
| HRP20210076T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma ezofagusa i drugih karcinoma | |
| HRP20202019T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora | |
| HRP20210698T1 (hr) | Peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma dojke i drugih karcinoma | |
| AR121383A2 (es) | Péptidos y combinación de péptidos y andamiajes para su uso en inmunoterapia contra carcinoma de células renales (rcc) y otros cánceres | |
| AR122964A2 (es) | Péptidos útiles en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cáncer | |
| JP2019515650A5 (hr) | ||
| RU2020113032A (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака | |
| JP2020182458A5 (hr) | ||
| JP2020198875A5 (hr) | ||
| JP2020191862A5 (hr) | ||
| JP2010534463A5 (hr) | ||
| EA201892021A1 (ru) | Трансфицированные t-клетки и t-клеточные рецепторы для применения в иммунотерапии раковых заболеваний | |
| HRP20211852T1 (hr) | Nova imunoterapija protiv nekoliko tumora, poput raka pluća, uključujući nsclc | |
| EA201891759A1 (ru) | Трансфицированные t-клетки и t-клеточные рецепторы для применения в иммунотерапии раковых заболеваний | |
| JP2013521789A5 (hr) | ||
| JP2017518037A5 (hr) | ||
| RS54204B1 (en) | NEW IMMUNOTHERAPY AGAINST BRAIN TUMOR | |
| HRP20240359T1 (hr) | Peptidi iz piwil1 | |
| HRP20191671T1 (hr) | Nova imunoterapija za liječenje nekoliko tumora krvi, kao što je akutna mijeloidna leukemija (aml) | |
| HRP20210528T1 (hr) | Novi peptidi i kombinacija peptida i njihovih skela za uporabu u imunoterapiji protiv kolorektalnog karcinoma i drugih karcinoma | |
| HRP20151313T1 (hr) | Nova imunoterapija protiv neuronskih tumora i tumora mozga |